Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models

Daniil Polykovskiy1,*, Alexander Zhebrak1,*, Benjamin Sanchez-Lengeling2, Sergey Golovanov3, Oktai Tatanov3, Stanislav Belyaev3, Rauf Kurbanov3, Aleksey Artamonov3, Vladimir Aladinskiy1, Mark Veselov1, Artur Kadurin1,4, Sergey Nikolenko5,3,§, Alán Aspuru-Guzik6,7,8,§ and Alex Zhavoronkov1,§

1Insilico Medicine, Inc. Johns Hopkins University, Rockville, MD 20850 USA
2Chemistry and Chemical Biology Department, Harvard University, Cambridge, MA 02143 USA
3Neuromation OU, Tallinn, 10111 Estonia
4Insilico Taiwan, Taipei City 115, Taiwan R.O.C
5National Research University Higher School of Economics, St. Petersburg, 190008, Russia
6Department of Chemistry and Department of Computer Science, University of Toronto, Toronto, Ontario M5S 3H6, Canada
7Vector Institute for Artificial Intelligence, Toronto, Ontario M5S 1M1, Canada
8Biologically-Inspired Solar Energy Program, Canadian Institute for Advanced Research (CIFAR), Toronto, Ontario M5S 1M1, Canada

*Equal contribution
§Correspondence: alex@insilicomedicine.com, alan@aspuru.com, snikolenko@gmail.com

Abstract

Deep generative models such as generative adversarial networks, variational autoencoders, and autoregressive models are rapidly growing in popularity for the discovery of new molecules and materials. In this work, we introduce MOlecular SEts (MOSES), a benchmarking platform to support research on machine learning for drug discovery. MOSES implements several popular molecular generation models and includes a set of metrics that evaluate the diversity and quality of generated molecules. MOSES is meant to standardize the research on molecular generation and facilitate the sharing and comparison of new models. Additionally, we provide a large-scale comparison of existing state of the art models and elaborate on current challenges for generative models that might prove fertile ground for new research. Our platform and source code are freely available at https://github.com/molecularsets/moses.

1 Introduction

Many challenges of the 21st century, from personalized healthcare to energy production and storage [1], are linked by material discovery and development. The discovery of new molecules can bring enormous societal and technological progress, potentially curing rare diseases and providing a pathway for personalized precision medicine [2]: disruptive advances are likely to come from unexplored regions of the set of all possible chemical compounds. But a complete exploration of the huge space of potential chemicals is computationally intractable. It has been estimated that the number of pharmacologically-sensible molecules is in the order of $10^{23}$ to $10^{80}$ compounds [3,4]. Furthermore, often this search space can be constrained based on known chemistry, patented molecules and desired qualities (e.g. solubility or toxicity). There have been many approaches to mapping and mining the space of possible molecules, including high throughput screening, combinatorial libraries, evolutionary algorithms, and other techniques [3,5]. The exponential growth of publicly available experimental data also increases popularity of machine learning applications in bioinformatics [2,10].
for predicting pharmacological properties of drugs [11], biomarker development [12–15], and target identification [16].

Over the last few years, advances in machine learning, and especially in deep learning have driven the design of new computational systems that improve with experience and are able to model increasingly complex phenomena. One approach that has been proven fruitful for the modeling of the distribution of molecular data has been deep generative models. Just as we can sample a random numbers from a random variable distribution, generative models learn to model a data distribution in a way amenable for sampling new data points or conditioning over certain properties.

Deep generative models have shown remarkable results in a wide range of settings, from generating synthetic images [17] and natural language texts [18], to the applications in biomedicine, including the design of DNA sequences [19], and aging research [20]. One important field of application for deep generative models lies in the inverse design of organic molecules [21]: for a given functionality (solubility, ease of synthesis, toxicity or presence of particular molecular fragments, etc.) we wish to find the perfect molecule that meets these requirements. The inverse design uses optimization, sampling, and search methods to navigate the manifold of the functionality of chemical space. A deep generative model fits these requirements, since it learns the manifold of desired functionality and allows to map this functionality back to the chemical space.

Part of the success of deep learning in different fields has been driven by ever-growing publicly available datasets and standard benchmark sets. These sets serve as a common measuring stick for newly developed models and optimization strategies; for example, when the field of computer vision had more or less worked the classical MNIST dataset of handwritten digits into the ground [22], larger and more complex datasets such as ImageNet [23] immediately took its place.

In the context of organic molecules, MoleculeNet [24] was introduced as a standardized benchmark suite for discriminative tasks such as regression and classification, but at present, there is no counterpart for generative models and generation tasks. We attribute this due to two main reasons: 1) lack of a common benchmark set and 2) lack of metrics. Both reasons are hard to tackle since any given molecular application will depend highly on the context. The molecules used for organic redox flow batteries will differ quite significantly from molecules for Malaria transmission blocking. Even for a common dataset, the desired qualities might differ greatly. For drug molecules, we sometimes seek a diverse set of molecules to avoid an already patented chemical space, but it can also be advantageous to find molecules that are quite similar in functionality and structure to a patented molecule while being different enough.

Furthermore, it is not immediately clear how to compare deep generative models. There is no clear-cut way to evaluate the quality of generated samples; in particular, the loss function of the model itself is seldom a good choice for final evaluation. Often the real validation test for a candidate sample requires experimental characterization either via multiple in-vitro experiments or a device prototype. Computational approaches for scoring molecules tend to suffer from a lack of accuracy (e.g., target-ligand interaction) or are too time-consuming (e.g., simulating the electronic structure).

In this work, we aim to tackle both of these problems by providing a unified implementation of a benchmark suite for molecular generation, including data preprocessing utilities, evaluation metrics, and state of the art molecular generation models. While it is clear there can be no single solution to
cover all molecular applications, we hope that these contributions will serve as a clear and unified testbed for current and future generative models.

In the following sections, we elaborate on the details of each of the features of MOSES and conclude with evaluation results on a molecular biology dataset along with a discussion on current challenges in molecular generation. We also highlight possible ideas for improvement in datasets outside of a molecular biology context, alternative representations of molecules, and improvements in metrics for the molecules. The pipeline of our framework is shown on Figure 1.

2 Dataset

Deep generative models require large datasets in order to learn patterns that can generalize and lead to new molecules. While large datasets of molecules exist, there is no commonly accepted standard dataset. The pharmaceutical industry has historically driven much of the large-scale development and testing of molecular libraries via virtual screening and high-throughput screening. As Table 1 shows, the largest datasets correspond to libraries utilized in medicinal chemistry.

Virtual screening libraries are often constructed from the application of common reactions to a set of seed molecules; the reactions are such that their products are predictable and easily performed in a laboratory setting while seed molecules are typically purchasable or easily synthesized or extracted from natural products. Even though the coverage of reactions tends to be a small subset of all possible reactions [25], the resulting combinations can lead to virtual libraries on the order of \(10^{14} - 10^{18}\) compounds[26]. Large datasets with experimentally characterized labeled data are quite valuable for constructing accurate models and libraries, so these tend to be closed-source and company-owned. Most current molecular generation applications utilize a subset of ZINC or ChEMBL molecules. For this purpose, we propose a biological molecule benchmark set refined from the ZINC database.

The set is based on the ZINC Clean Leads collection. It contains 4,591,276 molecules with molecular weight in the range from 250 to 350 Daltons, a number of rotatable bonds not greater than 7, and XlogP less than or equal to 3.5. We removed molecules containing charged atoms, atoms besides C, N, S, O, F, Cl, Br, H or cycles longer than 8 atoms. The molecules were filtered via medicinal chemistry filters (MCFs) and PAINS filters [27].

Medicinal chemistry filters are used to discard compounds containing so-called “structural alerts”. Molecules containing such moieties either bear unstable or reactive groups or undergo biotransformations resulting in the formation of toxic metabolites or intermediates. Herein, we present a list of routine MCFs for the rational pre-selection of compounds more appropriate for modern drug design and development. These include some electrophilic alkylating groups, such as Michael acceptors (MCF1-3), alkyl halides (MCF4), epoxide (MCF5), isocyanate (MCF6), aldehyde (MCF7), imine (Schiff base, MCF8), aziridine (MCF9) which are very liable for nucleophilic attack, e.g. by serine, lysine or amino group of cysteine. In many cases, it leads to unselective protein and/or DNA damage. Metabolism of hydrazine (MCF10) furnishes diazene intermediates (MCF11) which are also alkylating warheads. Monosubstituted furans (MCF12) and thiophenes (MCF13) are transformed into reactive intermediates via epoxidation. Their active metabolites irreversibly bind nucleophilic groups and modify proteins. Electrophilic aromatics (e.g. halopyridine, MCF14), oxidized anilines (MCF15) and disulfides (MCF16) are also highly reactive. In vivo, alkylators are trapped and inactivated by the thiol group of glutathione, which is a key natural antioxidant. Azides (MCF17) are highly toxic; compounds containing this functional group particularly cause genotoxicity. Aminals (MCF18) and acetals (MCF19) are frequently unstable and inappropriate in generated structures. In addition, virtual structures containing a large number of halogens (MCF20-22) should be excluded due to increased molecular weight and lipophilicity (insufficient solubility for oral administration), metabolic stability and toxicity. The detailed mechanism of toxicity for structure alerts mentioned above has been comprehensively described in [28, 29].

The final dataset contains 1,936,962 molecular structures. For experiments, we also provide a training, test and scaffold test sets containing 250, 10, and 10 thousand molecules respectively. The scaffold test set contains unique Bemis-Murcko scaffolds [35] that were not present in the training and test sets. We use this set to assess how well the model can generate previously unobserved scaffolds.
Table 1: Datasets for generation tasks.

| Dataset        | Size  | Purpose                                                      |
|----------------|-------|--------------------------------------------------------------|
| ZINC [30, 31]  | 980M  | Commercially available compounds for virtual screening       |
| ChEMBL [32]    | 2M    | A manually curated database of bioactive drug-like molecules  |
| SureChEMBL [33] | 17M   | Named compounds from chemical patents                        |
| eMolecules     | 18M   | Purchasable molecules                                       |
| SuperNatural   | 330k  | Natural product molecules                                   |
| DrugBank       | 10.5k | FDA approved drugs, experimental drugs, drugs available worldwide |

3 Representations

Before training a generative or predictive model on molecular data, one has to represent compounds in a machine learning-friendly way. For generative tasks, we often would like to have a one-to-one mapping between the molecule and its representation to do a quick search in a lookup table, perform reconstruction, or sample new molecules (see example in Figure 2). For the generative models considered in this work, we have focused on two primary forms of representation: sequences of tokens via SMILES [36, 37] and molecular graphs. Both representations rely on empirical principles of bonding, and a molecule is interpreted as an undirected graph where each atom is a node and the bonds are the edges. To reduce complexity, hydrogen atoms are treated implicitly because they are deduced from standard chemistry valence rules. A challenge when dealing with graphs is the graph isomorphism problem: without an explicit ordering of nodes, two graphs can map to the same structure and finding out whether they are equivalent is computationally demanding. This can be used for data augmentation purposes; but conversely, it has been argued that this representation degeneracy introduces noise to a model [38]. In this section, we expand on these two representations and also elaborate on other alternatives that might be used for generative models.

Figure 2: Different representations of a vanillin molecule.

SMILES. Any graph can be transformed into a sequence of tokens by traversing its spanning tree and collecting all visited edges and nodes as tokens. For molecules, the Simplified Molecular Input Line System, or SMILES, defines grammar and syntax rules that are widely adopted in the chemistry community. In order to remove ambiguity, SMILES supports a canonical ordering (canonical SMILES) [39]. Additionally, SMILES can also encode the stereochemistry by specifying special tokens for chirality (isomeric SMILES). A non-standard specification can also be adapted to include specific types of bonds, fragments, etc.

Much of the popularity behind SMILES in molecular generative models [40-48] has been due to the fast adaptation of sequence modeling tools such as recurrent neural networks, attention mechanisms, and dilated convolutions, among others, to the text nature of SMILES. However, in a string format, we cannot preserve locality of atoms, and some atoms that are adjacent in the molecular graph can appear in distant positions in a string. Also, not every string with SMILES tokens is semantically correct, i.e., represents a valid molecule, so a neural network has to track distant relationships in SMILES, which leads to a lower number of valid strings. Some methods try to incorporate SMILES
syntax into a network architecture to increase the fraction of valid molecules \([49, 50]\). There is also an International Chemical Identifier (InChI) \([51]\) format, which is a more verbose string representation, explicitly specifying a chemical formula, charges, hydrogens, and isotopes.

**Molecular graphs.** In a machine learning context, graphs are normally represented via sparse adjacency matrices with values corresponding to the presence or absence of edges between vertices. These matrices are augmented with node and edge feature vectors since nodes and edges in molecular graphs are likely to include physical properties related to the atoms and bonds. Often these are represented as sparse tensors \([52]\).

There are multiple ways of processing and taking into account information defined on a graph, and so several approaches have been proposed such as Graph Convolutional Networks \([53]\), Weave Networks \([24]\), and Message Passing Networks \([54]\). The molecular graph can be represented implicitly as an adjacency matrix with different atoms encoded along certain dimensions of the tensor; this approach has been successfully used in the MolGAN model \([55]\) for the QM9 dataset \([56]\). Another approach for treating graphs was introduced with the Junction Tree VAE model \([57]\), which, instead of modeling a molecular graph as an atom-wise graph, interprets each molecule as a composition of subgraphs chosen from a vocabulary of fragments.

**3D structure and alternative representations.** For a long time, one of the most common representations for molecular structures has been a fingerprint, a fixed-length vector indicating the presence or absence of a chemical environment \([58, 59]\). Fingerprints are not typically invertible but can be used for fast screening by similarity to available in-house compounds. Kadurin et al. \([47]\) implemented VAE and AAE models based on Molecular Access System (MACCS) fingerprints to screen for novel compounds with the desired effect. Polykovskiy et al. \([60]\) proposed a generative model for creating molecular structures for a given fingerprint, training a simple generator on fingerprints and then transforming them into SMILES with a separate model. However, fingerprints often lack biological relevance and do not fit into the process of designing novel compounds.

One shortcoming of using molecular graphs and SMILES to model chemical and physical phenomena is that they represent a description of molecules on the level of atoms. A complete description of a molecule will require to take into account their 3D coordinates, symmetries with respect to the Schrödinger equation, and possibly its electrons. This is a current open research problem, and therefore we would like to draw attention to other works that involve alternative representations for molecules and could be potentially used or expanded for generative models.

Another representation has relied on position molecules within a 3D grid space, often with channels for different types of atoms, where a voxel is non-zero when it contains an atom. This representation is quite flexible since it can also incorporate information about the binding position in an active site of a protein \([64, 65]\). One major challenge of this representation is sparsity; for this purpose, Kuzminykh et al. \([66]\) proposed an invertible smoothing transformation to reduce sparsity in the 3D space. Building generative models on 3D representations remains an open problem. One of the current approaches that allows to work directly in the 3D space is providing 3D coordinates to graph nodes or SMILES atoms.

**4 Metrics**

Generative models are supposed to produce a wide variety of different samples. Therefore, to evaluate generative models one has to compare sets of generated molecules, looking for coverage of the ground truth, diversity among generated objects, and similarity between various statistical properties of the generated set and the reference set. To this purpose, we have utilized five metrics that can be used to compare a generated set of molecules \(G\) and a reference set of molecules \(R\): fragment similarity, scaffold similarity, nearest neighbor similarity (based on Morgan structural fingerprints and Gobby
While SNN measures the dissimilarity to the reference dataset (external diversity), the internal diversity metric evaluates the generated molecules. This metric detects a common failure case of generative models—mode collapse. With mode collapse the model produces a limited variety of molecules with similar chemical structures that are encoded in these fingerprints. In this work, we used standard Morgan fingerprints with radius 2 and 1024 bits. This representation is useful for a general analysis of the chemical space considering the constant search for novel scaffolds and chemotypes which is an essential part of the modern drug discovery process.

In general, molecules with similar chemical structures tend to possess the same biological response, there are more common features called pharmacophores that are responsible for biological activity. It has been shown that structurally diverse ligands with common pharmacophore hypothesis can bind to the same receptor site [70]. Therefore, nearest neighbor similarity calculated using 2D pharmacophore fingerprints [59] can be beneficial when comparing two sets of molecules with regards to the biological targets they can bind to.

Internal diversity (IntDiv_p) [71] assesses the chemical diversity within the generated set of molecules G.

\[
\text{IntDiv}_p(G) = 1 - \sqrt{\frac{1}{|G|^2} \sum_{m_1, m_2 \in G} T(m_1, m_2)^p},
\]

(4)

While SNN measures the dissimilarity to the reference dataset (external diversity), the internal diversity metric evaluates the generated molecules. This metric detects a common failure case of generative models—mode collapse. With mode collapse the model produces a limited variety of samples, ignoring some areas of chemical space. A higher value of the metric corresponds to higher diversity in the generated set. In the experiments, we report \( \text{IntDiv}_1(G) \) and \( \text{IntDiv}_2(G) \). Fréchet ChemNet Distance (FCD) [72] is calculated using the penultimate layer of the deep neural network ChemNet trained to predict the biological activities of drugs. The activations represent both chemical and biological properties of the compounds. For two sets of molecules G and R, FCD is defined as

\[
\text{FCD}(G, R) = \| \mu_G - \mu_R \|^2 + tr \left( \Sigma_G + \Sigma_R - 2(\Sigma_G \Sigma_R)^{1/2} \right),
\]

(5)

where \( \mu_G, \mu_R \) are mean vectors and \( \Sigma_G, \Sigma_R \) are covariance matrices of the activations on the penultimate layer of ChemNet on the sets G and R respectively.
We believe that these five metrics provide a good coverage of various desirable properties of a set of generated molecules, and we propose to use them as standard metrics for the comparison of different generative models for molecular fingerprints and structures.

**Auxiliary Metrics.** For evaluation purposes, we have also included utilities for computing auxiliary metrics that represent qualities that are commonly used for small molecule drug discovery.

- **Molecular weight (MW):** the sum of atomic weights in a molecule.
- **LogP:** the water-octanol partition coefficient, a property that measures how likely a molecule is able to mix with water. Computed via RDKit’s Crippen [73] function.
- **Synthetics Accessibility Score (SA):** a heuristic estimate of how hard (10) or how easy (1) it is to synthesize a given molecule. SAscore is based on a combination of fragment contributions and a complexity penalty [74].
- **Quantitative Estimation of Drug-likeness (QED):** a 0 to 1 float value estimating how likely a molecule is a viable candidate for a drug. QED is meant to capture the abstract notion of aesthetics in medicinal chemistry [75].
- **Natural Product-likeness Score (NP):** a numerical estimate that can be used to determine if a molecule is likely to be a natural product (0 . . . 5), a drug molecule (−3 . . . 3) or a synthetic product (−5 . . . 0). This score is calculated from several substructure descriptors and comparing them to the properties of other distributions of molecules [76].

To quantitatively compare the distributions in the generated and test sets, we use the Fréchet distance. Alternatively, distributions of molecules can be compared in a simplified manner by looking at the mean and variance of properties.

5 Models

In the current version of MOSES, we implemented several deep learning models that cover different approaches to molecule generation problem such as language models modeled as character-level recurrent neural networks (CharRNN) [41, 72], Variational and Adversarial Autoencoders (VAE [77–79], AAE [80, 78, 60]), Junction Tree Variational Autoencoders (JT-VAE). These baseline models are trained in an unsupervised or semi-supervised fashion. Most models are based on the SMILES representation of a molecule and as such will typically incorporate sequence modeling tools such as recurrent neural networks (RNN) with different types of cells. There are many new models coming out dealing with other representation of molecules such as the JT-VAE which works with molecular graphs as tensors. Although more models will be added, we believe the current coverage in the collection is sufficient for good comparison of any arbitrary new model.

Model comparison can be challenging since different training parameters (number of epochs, batch size, learning rate, initial state, optimizer) and architecture hyperparameters (hidden layer dimension, number of layers, etc.) can significantly alter their performance. For each model, we attempted to preserve its original architecture as published and tweaked hyperparameters to improve performance. We used random search over 100 architectures for every model and selected the architecture that produced the highest chemical validity. For models with the same validity, we chose models with the highest uniqueness. All models are implemented with Python 3 utilizing the PyTorch [81] framework. Next, we briefly introduce these models.

**Character-level recurrent neural networks (CharRNN)** [41] treats the task of generating SMILES as a language model attempting to learn the statistical structure of SMILES syntax by training it on a large corpus of SMILES (Figure 3). Model parameters are optimized using maximum likelihood estimation (MLE). CharRNN is implemented using Long Short-Term Memory [82] RNN cells stacked into 3 layers with hidden dimension 768 each. We used a dropout [83] layer with dropout rate 0.2. Softmax is utilized as an output layer. Training is done with a batch size of 64, using the Adam [84] optimizer for 50 epochs with a learning rate of $10^{-3}$ halved after each 10 epochs.

**Variational autoencoder (VAE)** is a framework for training two neural networks—an encoder and a decoder—to learn a mapping from high-dimensional data representation into a lower-dimensional space and back. The lower-dimensional space is called the latent space, which is often a continuous vector space with normally distributed latent representation. VAE parameters are optimized to encode
Figure 3: CharRNN model. A model is trained by maximizing the likelihood of known molecules.

and decode data by minimizing the reconstruction loss while also minimizing a KL-divergence term arising from the variational approximation that can loosely be interpreted as a regularization term (Figure 4). Since molecules are discrete objects, properly trained VAE defines an invertible continuous representation of a molecule.

A VAE-based architecture for the molecular generation was initially proposed by Gómez-Bombarelli et al. [77], and alternative architectures have been proposed by Kadurin et al. [78] and Blaschke et al. [79]. We combine aspects from both implementations in MOSES. Utilizing a bidirectional [85] Gated Recurrent Unit (GRU) [86] with a linear output layer as an encoder. The decoder is a 3-layer GRU of 512 hidden dimensions with intermediate dropout layers with dropout probability 0.2. Training is done with a batch size of 128, utilizing a gradient clipping of 50, KL-term weight linearly increased from 0 to 1 during training. We optimized the model using Adam optimizer with a learning rate of $3 \cdot 10^{-4}$. We trained the model for 50 epochs.

Figure 4: Autoencoder-based models. VAE/AAE forms a specific distribution in the latent space.

Adversarial Autoencoders (AAE) [80] combine the idea of VAE with that of adversarial training as found in GAN. One of the main drawbacks of VAE is the KL divergence term that has a closed-form analytical solution only for a handful of distributions. In AAE, the KL divergence term is avoided by training a discriminator network to predict whether a given sample came from the latent space of the AE or from a prior distribution. Parameters are optimized to minimize the reconstruction loss and to minimize the discriminator loss. Kadurin et al. [78] applied AAE architecture to the drug generation task. The model consists of an encoder with a 1-layer bidirectional LSTM with 512 hidden dimensions, a decoder with a 2-layer LSTM with 512 hidden dimensions and a shared embedding of size 16. The discriminator network is a 2-layer fully connected neural network with 640 and 256 nodes respectively with exponential linear unit (ELU) [87] activation function [88]. Training is done with a batch size of 128, with the Adam optimizer using a learning rate of $10^{-3}$ for 50 epochs. We halved the learning rate after each 10 epochs.
Table 2: Performance metrics for baseline models: fraction of valid molecules, fraction of unique molecules from 1,000 and 10,000 molecules, internal diversity, fraction of molecules passing filters (MCF, PAINS, ring sizes, charges, atom types).

| Model    | Valid (↑) | Unique@1k (↑) | Unique@10k (↑) | IntDiv (↑) | IntDiv2 (↑) | Filters (↑) |
|----------|-----------|---------------|----------------|-------------|-------------|-------------|
| Train    | 1.0       | 1.0           | 1.0            | 0.857       | 0.851       | 1.0         |
| CharRNN  | 0.809     | 1.0           | 1.0            | 0.855       | 0.849       | 0.975       |
| AAE      | 0.997     | 1.0           | 0.995          | **0.857**   | 0.85         | **0.997**   |
| VAE      | 0.969     | 1.0           | 0.999          | 0.856       | **0.851**   | 0.996       |
| JT-VAE   | 1.0       | 1.0           | 0.999          | 0.851       | 0.845       | 0.978       |

Table 3: Scaffold split metrics for baseline models: Fréchet ChemNet Distance (FCD), Similarity to the nearest neighbour (SNN), Fragment similarity (Frag), Scaffold similarity (Scaf).

| Model    | FCD (↓)  | SNN (↑)  | Frag (↑)  | Scaf (↑)  |
|----------|----------|----------|-----------|-----------|
| Train    | Test     | TestSF   | Test      | TestSF    |
|          | 0.008    | 0.476    | 0.642     | 0.586     |
| CharRNN  | 0.355    | 0.899    | 0.536     | 0.514     |
| AAE      | 0.395    | 1.0      | 0.62      | 0.575     |
| VAE      | 0.084    | **0.541**| **0.623** | **0.577** |
| JT-VAE   | 0.422    | 0.996    | 0.556     | 0.527     |

Junction Tree VAE (JT-VAE) [89] is one of the first deep generative models that explicitly made use of a graph representation of molecules. The JT-VAE generates molecules in two phases by exploiting valid subgraphs as components. In the first phase, it generates a tree-structured object (a junction tree) whose role is to represent the scaffold of subgraph components and their coarse relative arrangements. The components are valid chemical substructures automatically extracted from the training set using tree decomposition and are then used as building blocks. In the second phase, the subgraphs (nodes of the tree) are assembled together into a coherent molecular graph. We report the experimental results from the official JT-VAE repository [90].

6 Results

We trained baseline models on the proposed dataset and tuned hyperparameters independently to achieve minimal FCD score on the test dataset. In Table 2 and Table 3, we provide metrics implemented within the MOSES platform. The most up-to-date version of the comparison table can be found at https://github.com/molecularsets/moses. According to the experiments, VAE outperforms other architectures on the Fréchet ChemNet distance metric (FCD), suggesting the VAE describe the chemical space better than other models. AAE is better in discovering novel scaffolds as suggested by Scaff/TestSF metric. All models successfully learn SMILES syntax, as indicated by Valid metric. In Figure 5, we compare distributions of chemical properties in generated and reference sets. We notice, that most of the models match the shape of the distribution, although some models (AAE and JT-VAE) expose bias towards more complex molecules, as SA score is on average higher for generated molecules than for the reference dataset.

7 Discussion

With MOSES, we have designed a molecular generation benchmark platform that combines several existing state-of-the-art baseline models and several evaluation metrics. This platform should allow for a fair and comprehensive comparison of new generative models. Providing a one-size-fits-all solution for a given molecular application is not possible since the constraints, chemistry, and properties of interest are highly varied and very specific for a given context. We design MOSES as the first baseline of comparison, providing metrics that allow taking into account several perspectives relevant to molecular generation. For future work on this project, we will keep extending the MOSES repository with new baseline models, updated evaluation tables, as well as incorporating new evaluation metrics.
We also wish to highlight and re-emphasize several research directions and challenges that future generative models and efforts should tackle.

- **Organic material datasets.** While most easily available datasets cover biological contexts, there is a need for large high-quality datasets corresponding to organic materials for redox flow batteries, light emitting diodes, solar cell, dyes, polymers and copolymers, odorants, crop protectants, and food preservatives.

- **Non-atom centric representations of molecules.** Most generative models have focused on the usage of molecular graph either explicitly or as SMILES. To be able to describe more accurately and completely molecular processes we might need representations that include information related to electrons or 3D structure of a molecule.

- **Hierarchical representations of molecules.** As noted with JT-VAE, a hierarchical model might be able to leverage structure at different scales (atoms, fragments, etc.). This might prove important towards moving from small molecules to proteins, where the number of atoms can be on the order of thousands. Structured representations might benefit from reduced complexity, in processing time but also for prediction.

- **Better and more general metrics.** Current auxiliary metrics have been developed around heuristics and rules of medicinal chemistry, often validated with small datasets due to the lack of publicly available datasets. To build better guided generative models we need more accurate metrics that go beyond just medicinal chemistry. Measuring the synthetic accessibility, and cost of synthesis of a molecule, incorporating reaction path between commercially available reactants and natural products is important [91], as well as measuring reliably solubility and miscibility between materials, in a variety of molecules environments [92].

- **Guided and biased generation.** There have been several demonstrations of being able to bias the generative process of models using reinforcement learning [93-95], often these methods...
Monte Carlo Tree Search) are data intensive, so more efficient RL optimization methods are needed. For areas of application that deserve attention are the generation of symmetry-point group preserving molecules and navigation around patented molecular space. The former is important for planning and simplifying synthesis, the latter for promoting or avoiding certain types of substructures.

We hope this work enables future researchers interested in tackling molecular and material challenges.

References

[1] Daniel P Tabor, Loïc M Roch, Semion K Saikin, Christoph Kreisbeck, Dennis Sheberla, Joseph H Montoya, Shyam Dwaraknath, Muratahan Aykol, Carlos Ortiz, Hermann Tribukait, Carlos Amador-Bedolla, Christoph J Brabec, Benji Maruyama, Kristin A Persson, and Alán Aspuru-Guzik. Accelerating the discovery of materials for clean energy in the era of smart automation. *Nature Reviews Materials*, 3(5):5–20, April 2018.

[2] Su-In Lee, Safiye Celik, Benjamin A Logsdon, Scott M Lundberg, Timothy J Martins, Vivian G Oehler, Elihu H Estey, Chris P Miller, Sylvia Chien, Jin Dai, Akanksha Saxena, C Anthony Blau, and Pamela S Becker. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. *Nat. Commun.*, 9(1):42, January 2018.

[3] Jean-Louis Reymond. The chemical space project. *Acc. Chem. Res.*, 48(3):722–730, 2015.

[4] Peter Kirkpatrick and Clare Ellis. Chemical space. *Nature*, 432(7019):823–823, December 2004.

[5] Stefano Curtarolo, Gus L W Hart, Marco Buongiorno Nardelli, Natalio Mingo, Stefano Sanvito, and Ohad Levy. The high-throughput highway to computational materials design. *Nat. Mater.*, 12(3):191–201, March 2013.

[6] Xiangqian Hu, David N Beratan, and Weitao Yang. Emergent strategies for inverse molecular design. *Sci. China B*, 52(11):1769–1776, November 2009.

[7] Tu C Le and David A Winkler. Discovery and optimization of materials using evolutionary approaches. *Chem. Rev.*, 116(10):6107–6132, May 2016.

[8] Edward O Pyzer-Knapp, Changwon Suh, Rafael Gómez-Bombarelli, Jorge Aguilera-Parraguez, and Alán Aspuru-Guzik. What is High-Throughput virtual screening? a perspective from organic materials discovery. *Annu. Rev. Mater. Res.*, 45(1):195–216, 2015.

[9] Travers Ching, Daniel S. Himmelstein, Brett K. Beaulieu-Jones, Alexandr A. Kalinin, Brian T. Do, Gregory P. Way, Enrico Ferrero, Paul-Michael Agapow, Michael Zietz, Michael M. Hoffman, Wei Xie, Gail L. Rosen, Benjamin J. Lengerich, Johnny Israeli, Jack Lanchantin, Stephen Woloszynek, Anne E. Carpenter, Avanti Shrikumar, Jinbo Xu, Evan M. Cofer, Christopher A. Lavender, Srinivas C. Turaga, Amr M. Alexandari, Zhiyong Lu, David J. Harris, Dave DeCaprio, Yanjun Qi, Anshul Kundaje, Yifan Peng, Laura K. Wiley, Marwin H. S. Segler, Simina M. Boca, S. Joshua Swamidass, Austin Huang, Anthony Gitter, and Casey S. Greene. Opportunities and obstacles for deep learning in biology and medicine. *Journal of The Royal Society Interface*, 15 (141):20170387, apr 2018. doi: 10.1098/rsif.2017.0387. URL [https://doi.org/10.1098/rsif.2017.0387](https://doi.org/10.1098/rsif.2017.0387).

[10] Polina Mamoshina, Armando Vieira, Evgeny Putin, and Alex Zhavoronkov. Applications of deep learning in biomedicine. *Molecular Pharmaceutics*, 13(5):1445–1454, mar 2016.

[11] A. Aliper, S. Plis, A. Artemov, A. Ulloa, P. Mamoshina, and A. Zhavoronkov. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. *Mol. Pharm.*, 13(7):2524–2530, 07 2016.

[12] E. Putin, P. Mamoshina, A. Aliper, M. Korzinkin, A. Moskalev, A. Kolosov, A. Ostrovskiy, C. Cantor, J. Vijg, and A. Zhavoronkov. Deep biomarkers of human aging: Application of deep neural networks to biomarker development. *Aging (Albany NY)*, 8(5):1021–1033, 05 2016.
[13] Alex Zhavoronkov. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. *Molecular Pharmaceutics*, 15(10):4311–4313, 2018. doi: 10.1021/acs.molpharmaceut.8b00930. URL https://doi.org/10.1021/acs.molpharmaceut.8b00930

[14] Polina Mamoshina, Kirill Kochetov, Evgeny Putin, Franco Cortese, Alexander Aliper, Won-Suk Lee, Sung-Min Ahn, Lee Uhn, Neil Skjodt, Olga Kovalchuk, Morten Scheibye-Knudsen, and Alex Zhavoronkov. Population specific biomarkers of human aging: A big data study using south korean, canadian, and eastern european patient populations. *The Journals of Gerontology: Series A*, page gly005, 2018. doi: 10.1093/gerona/gly005. URL http://dx.doi.org/10.1093/gerona/gly005

[15] M. D. West, I. Labat, H. Sternberg, D. Larocca, I. Nasonkin, K. B. Chapman, R. Singh, E. Makarev, A. Aliper, A. Kazennov, A. Alekseenko, N. Shuvalov, E. Cheskidova, A. Alekseev, A. Artemov, E. Putin, P. Mamoshina, N. Pryanichnikov, J. Larocca, K. Copeland, E. Izumchenko, M. Korzinkin, and A. Zhavoronkov. Use of deep neural network ensembles to identify embryonic-fetal transition markers: repression of COX7A1 in embryonic and cancer cells. *Oncotarget*, 9(8):7796–7811, Jan 2018.

[16] Polina Mamoshina, Marina Volosnikova, Ivan V. Ozerov, Evgeny Putin, Ekaterina Skibina, Franco Cortese, and Alex Zhavoronkov. Machine learning on human muscle transcriptomic data for biomarker discovery and tissue-specific drug target identification. *Frontiers in Genetics*, 9:242, 2018. ISSN 1664-8021. doi: 10.3389/fgene.2018.00242. URL https://www.frontiersin.org/article/10.3389/fgene.2018.00242

[17] Tero Karras, Timo Aila, Samuli Laine, and Jaakko Lehtinen. Progressive growing of GANs for improved quality, stability, and variation. October 2017.

[18] Lantao Yu, Weinan Zhang, Jun Wang, and Yong Yu. SeqGAN: Sequence generative adversarial nets with policy gradient. September 2016.

[19] Nathan Killoran, Leo J Lee, Andrew Delong, David Duvenaud, and Brendan J Frey. Generating and designing DNA with deep generative models. December 2017.

[20] Alex Zhavoronkov, Polina Mamoshina, Quentin Vanhaelen, Morten Scheibye-Knudsen, Alexey Moskalev, and Alex Aliper. Artificial intelligence for aging and longevity research: Recent advances and perspectives. *Ageing Research Reviews*, 49:49–66, jan 2019. doi: 10.1016/j.arr.2018.11.003. URL https://doi.org/10.1016/j.arr.2018.11.003

[21] Benjamin Sanchez-Lengeling and Alán Aspuru-Guzik. Inverse molecular design using machine learning: Generative models for matter engineering. *Science*, 361(6400):360–365, July 2018.

[22] Yann LeCun, Corinna Cortes, and Christopher Burges. The MNIST database of handwritten digits. http://yann.lecun.com/exdb/mnist/

[23] J Deng, W Dong, R Socher, L-J Li, K Li, and L Fei-Fei. ImageNet: A Large-Scale Hierarchical Image Database. In *CVPR*09, 2009.

[24] Zhenqin Wu, Bharath Ramsundar, Evan N Feinberg, Joseph Gomes, Caleb Geniesse, Aneesh S Pappu, Karl Leswing, and Vijay Pande. MoleculeNet: a benchmark for molecular machine learning. *Chem. Sci.*, 9(2):513–530, January 2018.

[25] Nadine Schneider, Daniel M Lowe, Roger A Sayle, Michael A Tarselli, and Gregory A Landrum. Big data from pharmaceutical patents: A computational analysis of medicinal chemists' bread and butter. *J. Med. Chem.*, 59(9):4385–4402, May 2016.

[26] W Patrick Walters. Virtual chemical libraries. *J. Med. Chem.*, September 2018.

[27] Jonathan B Baell and Georgina A Holloway. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J. Med. Chem.*, 53(7):2719–2740, April 2010.
[28] Amit S Kalgutkar, Iain Gardner, R Scott Obach, Christopher L Shaffer, Ernesto Callegari, Kirk R Henne, Abdul E Mutlib, Deepak K Dalvie, Jae S Lee, Yasuhiro Nakai, John P O’Donnell, Jason Boer, and Shawn P Harriman. A comprehensive listing of bioactivation pathways of organic functional groups. *Curr. Drug Metab.*, 6(3):161–225, June 2005.

[29] Amit S Kalgutkar and John R Soglia. Minimising the potential for metabolic activation in drug discovery. *Expert Opin. Drug Metab. Toxicol.*, 1(1):91–142, June 2005.

[30] John J Irwin and Brian K Shoichet. ZINC — a free database of commercially available compounds for virtual screening. ZINC - a free database of commercially available compounds for virtual screening. *J. Chem. Inf. Model.*, 45(December 2004):177–182, 2005.

[31] Teague Sterling and John J Irwin. ZINC 15 - ligand discovery for everyone. *J. Chem. Inf. Model.*, 55(11):2324–2337, November 2015.

[32] Anna Gaulton, Anne Hersey, Michał Nowotka, A Patrícia Bento, Jon Chambers, David Mendez, Prudence Mutowod, Francis Atkinson, Louisa J Bellis, Elena Cibrián-Uhalte, Mark Davies, Nathan Dedman, Anneli Karlsson, Maria Paula Magariños, John P Overington, George Papadatos, Ines Smit, and Andrew R Leach. The ChEMBL database in 2017. *Nucleic Acids Res.*, 45(D1):D945–D954, January 2017.

[33] George Papadatos, Mark Davies, Nathan Dedman, Jon Chambers, Anna Gaulton, James Siddle, Richard Koks, Sean A Irvine, Joe Pettersson, Nicko Goncharoff, Anne Hersey, and John P Overington. SureChEMBL: a large-scale, chemically annotated patent document database. *Nucleic Acids Res.*, 44(D1):D1220–8, January 2016.

[34] Priyanka Banerjee, Jevgeni Erehman, Björn-Oliver Gohlke, Thomas Wilhelm, Robert Preissner, and Mathias Dunkel. Super natural II–a database of natural products. *Nucleic Acids Res.*, 43 (Database issue):D935–9, January 2015.

[35] G W Bemis and M A Murcko. The properties of known drugs. 1. molecular frameworks. *J. Med. Chem.*, 39(15):2887–2893, July 1996.

[36] David Weininger. SMILES, a chemical language and information system. 1. introduction to methodology and encoding rules. *J. Chem. Inf. Comput. Sci.*, 28(1):31–36, February 1988.

[37] David Weininger, Arthur Weininger, and Joseph L Weininger. SMILES. 2. algorithm for generation of unique SMILES notation. *J. Chem. Inf. Comput. Sci.*, 29(2):97–101, May 1989.

[38] O Anatole von Lilienfeld. First principles view on chemical compound space: Gaining rigorous atomistic control of molecular properties. *Int. J. Quantum Chem.*, 113(12):1676–1689, June 2013.

[39] Noel M O’Boyle. Towards a universal SMILES representation - a standard method to generate canonical SMILES based on the InChI. *J. Cheminform.*, 4(1):22, 2012.

[40] Mariya Popova, Olexandr Isayev, and Alexander Tropsha. Deep reinforcement learning for de novo drug design. *Sci Adv.*, 4(7):eaap7885, July 2018.

[41] Marwin H S Segler, Thierry Kogej, Christian Tyrchan, and Mark P Waller. Generating focused molecule libraries for drug discovery with recurrent neural networks. *ACS Cent Sci.*, 4(1):120–131, January 2018.

[42] Natasha Jaques, Shixiang Gu, Dzmitry Bahdanau, José Miguel Hernández-Lobato, Richard E Turner, and Douglas Eck. Sequence tutor: Conservative Fine-Tuning of sequence generation models with KL-control. *arXiv*, November 2016.

[43] Gabriel Lima Guimaraes, Benjamin Sanchez-Lengeling, Pedro Luis Cunha Farias, and Alán Aspuru-Guzik. Objective-Reinforced generative adversarial networks (ORGAN) for sequence generation models. *arXiv*, May 2017.

[44] Marcus Olivecrona, Thomas Blaschke, Ola Enkqvist, and Hongming Chen. Molecular de-novo design through deep reinforcement learning. *J. Cheminform.*, 9(1):48, December 2017.
[45] Seokho Kang and Kyunghyun Cho. Conditional molecular design with deep generative models. *J. Chem. Inf. Model.*, July 2018.

[46] Xiufeng Yang, Jinzhe Zhang, Kazuki Yoshizoe, Kei Terayama, and Koji Tsuda. ChemTS: an efficient python library for de novo molecular generation. *Sci. Technol. Adv. Mater.*, 18(1): 972–976, November 2017.

[47] Artur Kadurin, Sergey Nikolenko, Kuzma Khrabrov, Alex Aliper, and Alex Ahavoronkov. druGAN: An advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico. *Mol. Pharm.*, 14(9):3098–3104, September 2017.

[48] Evgeny Putin, Arip Asadulaev, Quentin Vanhaelen, Yan Ivanenkov, Anastasia V Aladinskaya, Alex Aliper, and Alex Zhavoronkov. Adversarial threshold neural computer for molecular de novo design. *Mol. Pharm.*, 15(10):4386–4397, October 2018.

[49] Matt J Kusner, Brooks Paige, and José Miguel Hernández-Lobato. Grammar variational autoencoder. March 2017.

[50] Hanjun Dai, Yingtao Tian, Bo Dai, Steven Skiena, and Le Song. Syntax-Directed variational autoencoder for structured data. February 2018.

[51] The IUPAC international chemical identifier (InChI). *Chemistry International – News magazine for IUPAC*, 31(1), January 2009.

[52] Jiaxuan You, Rex Ying, Xiang Ren, William Hamilton, and Jure Leskovec. GraphRNN: Generating realistic graphs with deep auto-regressive models. In *International Conference on Machine Learning*, pages 5694–5703, 2018.

[53] David Duvenaud, Dougal Maclaurin, Jorge Aguilera-Iparraguirre, Rafael Gómez-Bombarelli, Timothy Hirzel, Alán Aspuru-Guzik, and Ryan P Adams. Convolutional networks on graphs for learning molecular fingerprints. September 2015.

[54] Justin Gilmer, Samuel S Schoenholz, Patrick F Riley, Oriol Vinyals, and George E Dahl. Neural message passing for quantum chemistry. April 2017.

[55] Nicola De Cao and Thomas Kipf. MolGAN: An implicit generative model for small molecular graphs. May 2018.

[56] Raghunathan Ramakrishnan, Pavlo O Dral, Matthias Rupp, and O Anatole von Lilienfeld. Quantum chemistry structures and properties of 134 kilo molecules. *Scientific Data*, 1:140022, August 2014.

[57] Wengong Jin, Regina Barzilay, and Tommi Jaakkola. Junction tree variational autoencoder for molecular graph generation. In Jennifer Dy and Andreas Krause, editors, *Proceedings of the 35th International Conference on Machine Learning*, volume 80 of *Proceedings of Machine Learning Research*, pages 2323–2332, Stockholmsmässan, Stockholm Sweden, 2018. PMLR.

[58] David Rogers and Mathew Hahn. Extended-connectivity fingerprints. *J. Chem. Inf. Model.*, 50 (5):742–754, May 2010.

[59] A Gobbi and D Poppinger. Genetic optimization of combinatorial libraries. *Biotechnol. Bioeng.*, 61(1):47–54, 1998.

[60] Daniil Polykovskiy, Alexander Zhebrak, Dmitry Vetrov, Yan Ivanenkov, Vladimir Aladinskiy, Polina Mamoshina, Marine Bozdaganyan, Alexander Aliper, Alex Zhavoronkov, and Artur Kadurin. Entangled conditional adversarial autoencoder for de novo drug discovery. *Mol. Pharm.*, September 2018.

[61] Matthias Rupp, Alexandre Tkatchenko, Klaus-Robert Müller, and O Anatole von Lilienfeld. Fast and accurate modeling of molecular atomization energies with machine learning. *Phys. Rev. Lett.*, 108(5):058301, February 2012.
[62] Truong Son Hy, Shubhendu Trivedi, Horace Pan, Brandon M Anderson, and Risi Kondor. Predicting molecular properties with covariant compositional networks. *J. Chem. Phys.*, 148(24):241745, June 2018.

[63] Michael Eickenberg, Georgios Exarchakis, Matthew Hirn, Stéphane Mallat, and Louis Thiry. Solid harmonic wavelet scattering for predictions of molecule properties. *J. Chem. Phys.*, 148(24):241732, June 2018.

[64] Izhar Wallach, Michael Dzamba, and Abraham Heifets. AtomNet: A deep convolutional neural network for bioactivity prediction in structure-based drug discovery. October 2015.

[65] Joseph Gomes, Bharath Ramsundar, Evan N Feinberg, and Vijay S Pande. Atomic convolutional networks for predicting Protein-Ligand binding affinity. March 2017.

[66] Denis Kuzminykh, Daniil Polykovskiy, Artur Kadurin, Alexander Zhebrak, Ivan Baskov, Sergey Nikolenko, Rim Shayakhmetov, and Alex Zhavoronkov. 3D molecular representations based on the wave transform for convolutional neural networks. *Mol. Pharm.*, March 2018.

[67] J Degen, C Wegscheid-Gerlach, A Zaliani, and M Rarey. On the art of compiling and using 'drug-like' chemical fragment spaces. *ChemMedChem*, 3(10):1503–1507, 2008.

[68] Greg Landrum. RDKit: Open-source cheminformatics. [http://www.rdkit.org/](http://www.rdkit.org/).

[69] H L Morgan. The generation of a unique machine description for chemical Structures-A technique developed at chemical abstracts service. *J. Chem. Doc.*, 5(2):107–113, 1965.

[70] John H Van Drie. Monty kier and the origin of the pharmacophore concept. *Internet Electron. J. Mol. Des*, 6(9):271–279, 2007.

[71] Mostapha Benhenda. ChemGAN challenge for drug discovery: can AI reproduce natural chemical diversity? *CoRR*, abs/1708.08227, 2017.

[72] Kristina Preuer, Philipp Renz, Thomas Unterhiner, Sepp Hochreiter, and Günter Klambauer. Fréchet ChemNet distance: A metric for generative models for molecules in drug discovery. *J. Chem. Inf. Model.*, 58(9):1736–1741, September 2018.

[73] Scott A Wildman and Gordon M Crippen. Prediction of physicochemical parameters by atomic contributions. *J. Chem. Inf. Comput. Sci.*, 39(5):868–873, 1999.

[74] Peter Ertl and Ansgar Schuffenhauer. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. *J. Cheminform.*, 1(1):8, June 2009.

[75] G Richard Bickerton, Gaia V Paolini, Jérémy Besnard, Sorel Muresan, and Andrew L Hopkins. Quantifying the chemical beauty of drugs. *Nat. Chem.*, 4(2):90–98, January 2012.

[76] Peter Ertl, Silvio Roggo, and Ansgar Schuffenhauer. Natural product-likeness score and its application for prioritization of compound libraries. *J. Chem. Inf. Model.*, 48(1):68–74, January 2008.

[77] Rafael Gómez-Bombarelli, Jennifer N Wei, David Duvenaud, José Miguel Hernández-Lobato, Benjamin Sánchez-Lengeling, Derek Sheberla, Jorge Aguilera-Iparraguirre, Timothy D Hirzel, Ryan P Adams, and Alán Aspuru-Guzik. Automatic chemical design using a Data-Driven continuous representation of molecules. *ACS Central Science*, 4(2):268–276, February 2018.

[78] Artur Kadurin, Alexander Aliper, Andrey Kazennov, Polina Mamoshina, Quentin Vanhaelen, Kuzma Khрабров, and Alex Zhavoronkov. The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology. *Oncotarget*, 8(7):10883–10890, February 2017.

[79] Thomas Blaschke, Marcus Olivecrona, Ola Engkvist, Jürgen Bajorath, and Hongming Chen. Application of generative autoencoder in de novo molecular design. *Mol. Inform.*, 37(1-2), January 2018.
[80] Alireza Makhzani, Jonathon Shlens, Navdeep Jaitly, Ian Goodfellow, and Brendan Frey. Adversarial autoencoders. November 2015.

[81] Adam Paszke, Sam Gross, Soumith Chintala, Gregory Chanan, Edward Yang, Zachary DeVito, Zeming Lin, Alban Desmaison, Luca Antiga, and Adam Lerer. Automatic differentiation in pytorch. 2017.

[82] Sepp Hochreiter and Jürgen Schmidhuber. Long short-term memory. Neural Comput., 9(8): 1735–1780, 1997.

[83] Nitish Srivastava, Geoffrey Hinton, Alex Krizhevsky, Ilya Sutskever, and Ruslan Salakhutdinov. Dropout: a simple way to prevent neural networks from overfitting. The Journal of Machine Learning Research, 15(1):1929–1958, 2014.

[84] Diederik P Kingma and Jimmy Lei Ba. Adam: A method of stochastic optimization. International Conference on Learning Representations, pages 1–15, 2015.

[85] M Schuster and K K Paliwal. Bidirectional recurrent neural networks. IEEE Trans. Signal Process., 45(11):2673–2681, November 1997.

[86] Kyunghyun Cho, Bart van Merrienboer, Caglar Gulcehre, Dzmitry Bahdanau, Fethi Bougares, Holger Schwenk, and Yoshua Bengio. Learning phrase representations using RNN Encoder-Decoder for statistical machine translation. June 2014.

[87] Djork-Arné Clevert, Thomas Unterthiner, and Sepp Hochreiter. Fast and accurate deep network learning by exponential linear units (elus). International Conference on Learning Representations, 2016.

[88] Wengong Jin. Accelerated training of junction tree vae. GitHub, 2019. URL https://github.com/wengong-jin/icml18-jtnn/tree/master/fast_molvae.

[89] Andrea M E Palazzolo, Claire L W Simons, and Martin D Burke. The natural productome. Proc. Natl. Acad. Sci. U. S. A., 114(22):5564–5566, May 2017.

[90] Benjamin Sanchez-Lengeling, Loïc M Roch, José Darío Perea, Stefan Langner, Christoph J Brabec, and Alán Aspuru-Guzik. A bayesian approach to predict solubility parameters. Adv. Theory Simul., 17:1800069, September 2018.

[91] Benjamin Sanchez-Lengeling, Carlos Outeiral, Gabriel L Guimaraes, and Alan Aspuru-Guzik. Optimizing distributions over molecular space. an Objective-Reinforced generative adversarial network for inverse-design chemistry (ORGANIC). 2017.

[92] Marwin H S Segler, Mike Preuss, and Mark P Waller. Planning chemical syntheses with deep neural networks and symbolic AI. Nature, 555(7698):604–610, March 2018.

[93] Evgeny Putin, Arip Asadulaev, Yan Ivanenkov, Vladimir Aladinskiy, Benjamin Sanchez-Lengeling, Alán Aspuru-Guzik, and Alex Zhavoronkov. Reinforced adversarial neural computer for de novo molecular design. J. Chem. Inf. Model., 58(6):1194–1204, June 2018.